STAAR Surgical Company Share Price
Equities
STAA
US8523123052
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.89 USD | -3.49% |
|
-8.85% | -13.86% |
| Capitalization | 102.52Cr 87Cr 81Cr 76Cr 141.47Cr 9.39TCr 149.99Cr 925.19Cr 366.62Cr 4.44TCr 384.43Cr 376.56Cr 16TCr | P/E ratio 2025 * |
-16.9x | P/E ratio 2026 * | -6,870x |
|---|---|---|---|---|---|
| Enterprise value | 89Cr 76Cr 70Cr 66Cr 122.54Cr 8.13TCr 129.91Cr 801.33Cr 317.54Cr 3.84TCr 332.97Cr 326.15Cr 14TCr | EV / Sales 2025 * |
3.44x | EV / Sales 2026 * | 2.67x |
| Free-Float |
99.47% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: STAAR Surgical Company
| 1 day | -3.49% | ||
| 1 week | -8.85% | ||
| Current month | -13.86% | ||
| 1 month | -20.88% | ||
| 3 months | -25.48% | ||
| 6 months | +11.99% | ||
| Current year | -13.86% |
| 1 week | 19.4 |  | 21.27 |
| 1 month | 19.4 | | 24.28 |
| Current year | 19.4 | | 24.26 |
| 1 year | 13.5 | | 30.81 |
| 3 years | 13.5 | | 81.81 |
| 5 years | 13.5 | | 163.08 |
| 10 years | 4.98 | | 163.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Farrell
CEO | Chief Executive Officer | 61 | 26/02/2025 |
Deborah Andrews
DFI | Director of Finance/CFO | 68 | 28/04/2017 |
Warren Foust
PSD | President | 50 | 18/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Stephen Farrell
BRD | Director/Board Member | 61 | 01/01/2016 |
Lilian Zhou
BRD | Director/Board Member | 43 | 01/12/2023 |
Arthur Butcher
BRD | Director/Board Member | 55 | 12/03/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.49% | -8.85% | -13.56% | -71.84% | 102.52Cr | |
| -10.04% | -13.11% | -7.00% | -3.73% | 21TCr | |
| +1.05% | +2.63% | +14.66% | +25.25% | 13TCr | |
| +0.20% | +0.73% | +43.82% | +117.29% | 6.82TCr | |
| -0.07% | -0.67% | -14.28% | -18.82% | 5.87TCr | |
| +0.74% | -3.37% | +18.15% | +85.93% | 5.33TCr | |
| +6.14% | +5.87% | - | - | 3.6TCr | |
| +2.51% | +6.05% | -14.37% | -31.47% | 2.81TCr | |
| -0.11% | -1.27% | +20.19% | +27.20% | 2.56TCr | |
| +2.75% | -0.05% | +2.80% | -33.01% | 2.32TCr | |
| Average | -0.03% | -1.22% | +5.60% | +10.76% | 6.33TCr | |
| Weighted average by Cap. | -2.49% | -1.18% | +6.20% | +21.64% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 26Cr 22Cr 20Cr 19Cr 36Cr 2.36TCr 38Cr 232.61Cr 92Cr 1.12TCr 97Cr 95Cr 4.08TCr | 31Cr 27Cr 25Cr 23Cr 43Cr 2.88TCr 46Cr 284.06Cr 112.56Cr 1.36TCr 118.03Cr 115.62Cr 4.98TCr |
| Net income | -5.42Cr -4.61Cr -4.29Cr -4.02Cr -7.48Cr -496.63Cr -7.93Cr -49Cr -19Cr -234.6Cr -20Cr -20Cr -858.47Cr | -2L -2L -2L -2L -3L -2.24Cr -4L -22.07L -9L -1.06Cr -9L -9L -3.87Cr |
| Net Debt | -14Cr -12Cr -11Cr -10Cr -19Cr -1.26TCr -20Cr -123.85Cr -49Cr -593.78Cr -51Cr -50Cr -2.17TCr | -19Cr -16Cr -15Cr -14Cr -26Cr -1.7TCr -27Cr -167.39Cr -66Cr -802.53Cr -70Cr -68Cr -2.94TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 19.89 $ | -3.49% | 13,37,954 |
| 21/26/21 | 20.61 $ | -1.72% | 12,38,760 |
| 20/26/20 | 20.97 $ | 0.00% | 18,49,549 |
| 16/26/16 | 20.97 $ | 0.00% | 23,54,110 |
| 15/26/15 | 20.97 $ | -3.90% | 16,16,431 |
Delayed Quote Nasdaq, January 23, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- STAA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition